Although mTOR inhibitors have been used for enhancing protection against some bacterial and viral infections, and very recently in the treatment of cutaneous leishmaniasis [30], nothing is known about their effect in a vaccination protocol against VL. Here, MTOR is linked to cutaneous leishmaniasis.